Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Dawson James Initiates Coverage On Zomedica with Buy Rating, Announces Price Target of $6
Dawson James analyst Jason Kolbert initiates coverage on Zomedica (AMEX:ZOM) with a Buy rating and announces Price Target of $6.
Morgan Stanley Initiates Coverage On Otis Worldwide with Equal-Weight Rating, Announces Price Target of $84
Morgan Stanley analyst Joshua Pokrzywinski initiates coverage on Otis Worldwide (NYSE:OTIS) with a Equal-Weight rating and announces Price Target of $84.
Exane BNP Paribas Initiates Coverage On Equifax with Underperform Rating, Announces Price Target of $150
Exane BNP Paribas analyst Andy Grobler initiates coverage on Equifax (NYSE:EFX) with a Underperform rating and announces Price Target of $150.
Exane BNP Paribas Initiates Coverage On TransUnion with Neutral Rating, Announces Price Target of $64.5
Exane BNP Paribas analyst Andy Grobler initiates coverage on TransUnion (NYSE:TRU) with a Neutral rating and announces Price Target of $64.5.
Wells Fargo Initiates Coverage On Snowflake with Overweight Rating, Announces Price Target of $170
Wells Fargo analyst Michael Turrin initiates coverage on Snowflake (NYSE:SNOW) with a Overweight rating and announces Price Target of $170.
AppLovin Likely Stock For Additional Estimate Revisions Ahead Of Courtesy Secular And Fundamental Pressures, Analyst Says
Benchmark analyst Mark Zgutowicz initiated coverage on AppLovin Corp (NASDAQ: APP) with a S
Craig-Hallum Initiates Coverage On Tempo Automation Holdings with Hold Rating, Announces Price Target of $1
Craig-Hallum analyst Greg Palm initiates coverage on Tempo Automation Holdings (NASDAQ:TMPO) with a Hold rating and announces Price Target of $1.
Piper Sandler Initiates Coverage On Axsome Therapeutics with Neutral Rating, Announces Price Target of $75
Piper Sandler analyst David Amsellem initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Neutral rating and announces Price Target of $75.
Scotiabank Initiates Coverage On Guardant Health with Sector Outperform Rating, Announces Price Target of $36
Scotiabank analyst Sung Ji Nam initiates coverage on Guardant Health (NASDAQ:GH) with a Sector Outperform rating and announces Price Target of $36.